Related Experiment Video
Updated: Jul 6, 2026

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
Patient out-of-pocket costs for antihypertensive single pill combination products with cost caps
Catherine G Derington1,2, Kyle Tong3, Joshua A Jacobs4
1Department of Medicine, Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA. catherine.derington@cuanschutz.edu.
Abstract:
In this cross-sectional study of 5.8 million US adults with hypertension taking antihypertensive single-pill combination (SPC) products in the Medical Expenditure Panel Survey (2016-2022), the median out-of-pocket cost was $5.53 per SPC fill (interquartile range [IQR] $0.00-$12.70). A hypothetical small (e.g., $4/30 days) cost cap could reduce annual out-of-pocket spending by $152.9 million overall (median savings $5.35 (IQR $1.06-$12.81) per fill). A hypothetical large cost cap (e.g., $11/30 days) could reduce annual out-of-pocket spending by $61.2 million overall (median savings $2.27 (IQR $0.00-$11.28) per fill). Despite relatively low out-of-pocket costs, these spending reductions may lower patient financial burdens associated with antihypertensive SPC therapy.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Action of β1 Blockers
Peripheral Artery Disease III: Interprofessional Care
Antihypertensive Drugs: Types of β-Blockers